Liver Diseases Therapeutics Global Market Projected to Experience a Growth Rate of 7.8% CAGR, Reaching over $18.98 Billion By 2028 | Novartis AG, GlaxoSmithKline plc, Abbott Laboratories Inc., Pfizer Inc., Sanofi SA

The liver diseases therapeutics global market report 2024 from The Business Research Company provides comprehensive market statistics, including global market size, regional shares, competitor market share, detailed segments, trends, and opportunities. This report offers an in-depth analysis of current and future industry scenarios, delivering a complete perspective for thriving in the industrial automation software market.

Liver Diseases Therapeutics Market, 2024 report by The Business Research Company offers comprehensive insights into the current state of the market and highlights future growth opportunities.

Market Size –
The liver diseases therapeutics market size has grown strongly in recent years. It will grow from $13.02 billion in 2023 to $14.07 billion in 2024 at a compound annual growth rate (CAGR) of 8.0%. The growth in the historic period can be attributed to high prevalence of liver diseases, alcohol consumption patterns, advancements in diagnostics, obesity and metabolic syndrome, awareness and screening programs, government initiatives for hepatitis control.

The liver diseases therapeutics market size is expected to see strong growth in the next few years. It will grow to $18.98 billion in 2028 at a compound annual growth rate (CAGR) of 7.8%. The growth in the forecast period can be attributed to precision medicine approaches, innovations in rna therapeutics, focus on fibrosis treatments, patient advocacy and support groups, development of vaccines for hepatitis, regulatory support for orphan drugs. Major trends in the forecast period include advancements in treatment for hepatitis c, emergence of novel therapies for liver fibrosis, exploration of immunotherapies, telemedicine and remote monitoring, focus on nutritional interventions.

Order your report now for swift delivery @
https://www.thebusinessresearchcompany.com/report/liver-diseases-therapeutics-global-market-report

Scope Of Liver Diseases Therapeutics Market
The Business Research Company’s reports encompass a wide range of information, including:

1. Market Size (Historic and Forecast): Analysis of the market’s historical performance and projections for future growth.

2. Drivers: Examination of the key factors propelling market growth.

3. Trends: Identification of emerging trends and patterns shaping the market landscape.

4. Key Segments: Breakdown of the market into its primary segments and their respective performance.

5. Focus Regions and Geographies: Insight into the most critical regions and geographical areas influencing the market.

6. Macro Economic Factors: Assessment of broader economic elements impacting the market.

Liver Diseases Therapeutics Market Overview

Market Drivers –
The rising prevalence of liver diseases is expected to propel the growth of the liver disease therapeutics market going forward. Liver disease refers to any condition that has been affecting the liver. Liver disease therapeutics help in treating liver diseases through various treatments. For instance, in September 2023, according to reports shared by the American Liver Foundation, a US-based non-profit organization, liver disease had been detected in 4.5 million people (1.8%) in the US, and 51,642 adults in the U.S. died from liver disease in 2020. Therefore, the rising prevalence of liver diseases drives the growth of the liver disease therapeutics market.

Market Trends –
Strategic partnerships are a key trend gaining popularity in the liver disease therapeutics market. Major companies operating in the liver diseases therapeutics market are undergoing collaborations to strengthen their position in the liver diseases therapeutics market. For instance, in January 2022, Aligos Therapeutics Inc., a US-based clinical-stage biopharmaceutical company, collaborated with Merck & Co, a US-based company operating in liver disease therapeutics. This collaboration is to discover and develop oligonucleotide therapies for non-alcoholic steatohepatitis. Further, in January 2021, Novartis, a Switzerland-based company operating in liver disease therapeutics collaborated with Alnylam, a US-based biopharmaceutical company. This collaboration aims to develop liver-targeted therapy as a potential alternative to transplantation for patients experiencing liver failure.

The liver diseases therapeutics market covered in this report is segmented –
1) By Disease Type: Hepatitis, Non-Alcoholic Fatty Liver Disease, Alcohol-Induced, Liver Cancer
2) By Treatment: Antiviral, Vaccines, Chemotherapy, Immunosuppressive Agents, Corticosteroids
3) By End User: Hospitals, Ambulatory Surgery Centers, Other End Users

Get an inside scoop of the liver diseases therapeutics market, Request now for Sample Report @
https://www.thebusinessresearchcompany.com/sample.aspx?id=7969&type=smp

Regional Insights –
North America was the largest region in the liver diseases therapeutics market in 2023. Asia-Pacific is expected to be the fastest-growing region in the liver diseases therapeutics market report during the forecast period. The regions covered in the liver diseases therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Key Companies –
Major companies operating in the liver diseases therapeutics market report are Astellas Pharma Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche AG, Merck & Co. Inc., Novartis AG, GlaxoSmithKline plc, Abbott Laboratories Inc., Pfizer Inc., Sanofi SA, Johnson & Johnson Services Inc., Bayer AG, AbbVie Inc., Takeda Pharmaceutical Company Limited, Valeant Pharmaceuticals, Watson Pharmaceuticals Inc., AstraZeneca plc, Gilead Sciences Inc., Endo International plc, Alnylam Pharmaceuticals Inc., Provectus Biopharmaceuticals Inc., Intercept Pharmaceuticals Inc., Conatus Pharmaceuticals Inc., CymaBay Therapeutics Inc., Viking Therapeutics Inc., Madrigal Pharmaceuticals Inc., NGM Biopharmaceuticals Inc., Arrowhead Pharmaceuticals Inc., Dicerna Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., Enanta Pharmaceuticals Inc

Table of Contents
1. Executive Summary
2. Liver Diseases Therapeutics Market Report Structure
3. Liver Diseases Therapeutics Market Trends And Strategies
4. Liver Diseases Therapeutics Market – Macro Economic Scenario
5. Liver Diseases Therapeutics Market Size And Growth
…..
27. Liver Diseases Therapeutics Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Explore the trending research reports from TBRC
https://topprnews.com/gluten-feed-market

https://topprnews.com/organic-feed-market

https://topprnews.com/organic-pigments-market

https://goodprnews.com/rapeseed-oil-market

https://goodprnews.com/gluten-feed-market

https://goodprnews.com/manufactured-soil-market

 Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company

Twitter: https://twitter.com/tbrc_info

Facebook: https://www.facebook.com/TheBusinessResearchCompany

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Blog: https://blog.tbrc.info

Healthcare Blog: https://healthcareresearchreports.com

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model